Biotech Values

[DewDiligence]

FDA approves MRK Enflonsia for RSV prophylaxis:

https://www.businesswire.com/news/home/20250609303937/en/U.S.-FDA-Approves-Mercks-ENFLONSIA-clesrovimab-cfor-for-Prevention-of-Respiratory-Syncytial-Virus-RSV-Lower-Respiratory-Tract-Disease-in-Infants-Born-During-or-Entering-Their-First-RSV-Season

Please see #msg-176296921 for the (lack of) impact on ENTA’s RSV program.